Rettura Francesco, Bronzini Francesco, Campigotto Michele, Lambiase Christian, Pancetti Andrea, Berti Ginevra, Marchi Santino, de Bortoli Nicola, Zerbib Frank, Savarino Edoardo, Bellini Massimo
Division of Gastroenterology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Front Med (Lausanne). 2021 Nov 1;8:765061. doi: 10.3389/fmed.2021.765061. eCollection 2021.
Gastroesophageal reflux disease (GERD) is one of the most frequent gastrointestinal disorders. Proton pump inhibitors (PPIs) are effective in healing lesions and improving symptoms in most cases, although up to 40% of GERD patients do not respond adequately to PPI therapy. Refractory GERD (rGERD) is one of the most challenging problems, given its impact on the quality of life and consumption of health care resources. The definition of rGERD is a controversial topic as it has not been unequivocally established. Indeed, some patients unresponsive to PPIs who experience symptoms potentially related to GERD may not have GERD; in this case the definition could be replaced with "reflux-like PPI-refractory symptoms." Patients with persistent reflux-like symptoms should undergo a diagnostic workup aimed at finding objective evidence of GERD through endoscopic and pH-impedance investigations. The management strategies regarding rGERD, apart from a careful check of patient's compliance with PPIs, a possible change in the timing of their administration and the choice of a PPI with a different metabolic pathway, include other pharmacologic treatments. These include histamine-2 receptor antagonists (H2RAs), alginates, antacids and mucosal protective agents, potassium competitive acid blockers (PCABs), prokinetics, gamma aminobutyric acid-B (GABA-B) receptor agonists and metabotropic glutamate receptor-5 (mGluR5) antagonists, and pain modulators. If there is no benefit from medical therapy, but there is objective evidence of GERD, invasive antireflux options should be evaluated after having carefully explained the risks and benefits to the patient. The most widely performed invasive antireflux option remains laparoscopic antireflux surgery (LARS), even if other, less invasive, interventions have been suggested in the last few decades, including endoscopic transoral incisionless fundoplication (TIF), magnetic sphincter augmentation (LINX) or radiofrequency therapy (Stretta). Due to the different mechanisms underlying rGERD, the most effective strategy can vary, and it should be tailored to each patient. The aim of this paper is to review the different management options available to successfully deal with rGERD.
胃食管反流病(GERD)是最常见的胃肠道疾病之一。质子泵抑制剂(PPIs)在大多数情况下能有效愈合病变并改善症状,尽管高达40%的GERD患者对PPI治疗反应不佳。难治性胃食管反流病(rGERD)是最具挑战性的问题之一,因为它会影响生活质量并消耗医疗资源。rGERD的定义是一个有争议的话题,因为尚未明确确立。实际上,一些对PPIs无反应但出现可能与GERD相关症状的患者可能并没有GERD;在这种情况下,定义可替换为“类似反流的PPI难治性症状”。持续出现类似反流症状的患者应接受诊断性检查,旨在通过内镜和pH阻抗检查找到GERD的客观证据。rGERD的管理策略,除了仔细检查患者对PPIs的依从性、可能改变给药时间以及选择具有不同代谢途径的PPI外,还包括其他药物治疗。这些药物包括组胺-2受体拮抗剂(H2RAs)、藻酸盐、抗酸剂和黏膜保护剂、钾竞争性酸阻滞剂(PCABs)、促动力药、γ-氨基丁酸-B(GABA-B)受体激动剂和代谢型谷氨酸受体-5(mGluR5)拮抗剂以及疼痛调节剂。如果药物治疗无效,但有GERD的客观证据,则应在向患者仔细解释风险和益处后评估侵入性抗反流方案。即使在过去几十年中有人提出了其他侵入性较小的干预措施,包括内镜经口无切口胃底折叠术(TIF)、磁括约肌增强术(LINX)或射频治疗(Stretta),最广泛实施的侵入性抗反流方案仍然是腹腔镜抗反流手术(LARS)。由于rGERD的潜在机制不同,最有效的策略可能会有所不同,应针对每个患者进行量身定制。本文的目的是综述成功处理rGERD的不同管理方案。
Front Med (Lausanne). 2021-11-1
Clin Gastroenterol Hepatol. 2022-5
Clin Exp Gastroenterol. 2018-3-21
Gastroenterol Hepatol (N Y). 2014-9
Gastroenterol Hepatol (N Y). 2019-7
World J Methodol. 2025-12-20
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025-5
eGastroenterology. 2025-1-23
Dig Liver Dis. 2021-12
Drug Des Devel Ther. 2021
Neurogastroenterol Motil. 2021-1
Neurogastroenterol Motil. 2021-4
Aliment Pharmacol Ther. 2021-1
Am J Gastroenterol. 2021-2-1